[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100103725":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":13,"responsibleParty":7,"collaborators":7,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":7,"eligibilityCriteria":31,"healthyVolunteers":27,"sex":32,"minAge":33,"maxAge":34,"enrollmentInfo":35,"targetDuration":7,"studyType":38,"phases":39,"briefSummary":41,"conditions":42,"keywords":46,"overallStatus":49,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","AZD4877","10 mg IV (3 weeks treatment 1 week rest)",[14],{"facility":15,"status":7,"city":16,"state":7,"zip":7,"country":17,"countryCode":18,"cosmosGeoPoint":19,"geoPoint":24,"contacts":7},"Research Site","Fukuoka","Japan","JP",{"type":20,"coordinates":21},"Point",[22,23],130.41667,33.6,{"lat":23,"lon":22},"100103725","phase-1-a-phase-i-dose-escalation-study-to-assess-the-safety-and-drug-levels-in-blood-of-azd4877-in-japanese-adult-patients-100103725",false,"NCT00613652","A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients","A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly in Japanese Adult Patients With Advanced Solid Malignancies","Inclusion Criteria:\n\n* Patients diagnosed with solid tumour but which have no standard treatment or did not respond to previous treatments.\n* Patients who usually have mild symptoms capable of walking and light and sedentary work.\n* Patients who can stay in hospital at least during 4 weeks.\n\nExclusion Criteria:\n\n* Patients who have received treatment with anti-cancer agent within 4 weeks prior to first dose of study treatment; 6 weeks if the anti-cancer agent is mitomycin.\n* Patients with abnormally low levels of neutrophil count, platelet count, or haemoglobin, indicators of bone marrow function.\n* Patients who received therapeutic radiotherapy at central nervous system within 3 months prior to first dose of study treatment; the other sites within 4 weeks; or local site within 2 weeks.","ALL","20 Years","75 Years",{"count":36,"type":37},30,"ESTIMATED","INTERVENTIONAL",[40],"PHASE1","The primary purpose of this study is to evaluate the safety and tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies",[43,44,45],"Cancer","Tumors","Carcinoma",[47,48],"solid tumors","solid malignancies","COMPLETED","2009-07-20",{"date":52,"type":37},"2009-07-21",{"date":54,"type":7},"2008-01",{"date":56,"type":57},"2009-06","ACTUAL",{"name":5,"class":6},1]